Page 133 - 2019_08-Haematologica-web

DNMT3A mutation predicts adverse outcome in adult T-ALL
References
1. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424-2433.
2. Renneville A, Boissel N, Nibourel O, et al. Prognostic significance of DNA methyl- transferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia. 2012;26(6):1247-1254.
3. Gale RE, Lamb K, Allen C, et al. Simpson's paradox and the impact of different DNMT3A mutations on outcome in younger adults with acute myeloid leukemia. J Clin Oncol. 2015;33(18):2072- 2083.
4. Marcucci G, Metzeler KH, Schwind S, et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2012;30(7): 742-750.
5. Yan XJ, Xu J, Gu ZH, et al. Exome sequenc- ing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet. 2013;43(4):309-315.
6. Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28(2):241-247.
7. Stegelmann F, Bullinger L, Schlenk RF, et al. DNMT3A mutations in myeloproliferative neoplasms. Leukemia. 2011;25(7):1217- 1219.
8. Jankowska AM, Makishima H, Tiu RV, et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood. 2011;118(14): 3932-3941.
9. Roller A, Grossmann V, Bacher U, et al. Landmark analysis of DNMT3A mutations in hematological malignancies. Leukemia. 2013;27(7):1573-1578.
10. Van Vlierberghe P, Ambesi-Impiombato A, Perez-Garcia A, et al. ETV6 mutations in early immature human T cell leukemias. J Exp Med. 2011;208(13):2571-2579.
11. Grossmann V, Haferlach C, Weissmann S, et al. The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL. Genes Chromosomes Cancer. 2013;52(4):410-422.
12. Neumann M, Heesch S, Schlee C, et al. Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. Blood. 2013;121(23):4749-4752.
13. Van Vlierberghe P, Ambesi-Impiombato A, De Keersmaecker K, et al. Prognostic rele- vance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia. Blood.
2013;122(1):74-82.
14. Couronne L, Bastard C, Bernard OA. TET2
and DNMT3A mutations in human T-cell lymphoma. N Engl J Med. 2012;366(1):95- 96.
15. Sakata-Yanagimoto M, Enami T, Yoshida K, et al. Somatic RHOA mutation in angioim- munoblastic T cell lymphoma. Nat Genet. 2014;46(2):171-175.
16. Choi J, Goh G, Walradt T, et al. Genomic landscape of cutaneous T cell lymphoma. Nat Genet. 2015;47(9):1011-1019.
17. Ho PA, Kutny MA, Alonzo TA, et al. Leukemic mutations in the methylation- associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2011;57(2):204-209.
18. Huether R, Dong L, Chen X, et al. The land- scape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. Nat Commun. 2014;5:3630.
19. Shiba N, Taki T, Park MJ, et al. DNMT3A mutations are rare in childhood acute myeloid leukaemia, myelodysplastic syn- dromes and juvenile myelomonocytic leukaemia. Br J Haematol. 2012;156(3):413- 414.
Engl J Med. 2014;371(26):2477-2487.
28. Jaiswal S, Fontanillas P, Flannick J, et al. Age- related clonal hematopoiesis associated with adverse outcomes. N Engl J Med.
2014;371(26):2488-2498.
29. Xie M, Lu C, Wang J, et al. Age-related
mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20(12):1472-1478.
30. Shlush LI, Zandi S, Mitchell A, et al. Identification of pre-leukaemic haematopoi- etic stem cells in acute leukaemia. Nature. 2014;506(7488):328-333.
31. Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regula- tors and persist in remission. Proc Natl Acad Sci U S A. 2014;111(7):2548-2553.
32. Asnafi V, Beldjord K, Boulanger E, et al. Analysis of TCR, pT alpha, and RAG-1 in T- acute lymphoblastic leukemias improves understanding of early human T-lymphoid lineage commitment. Blood. 2003;101(7): 2693-2703.
33. Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a sub- type of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10(2):147-
20. Shen Y, Zhu YM, Fan X, et al. Gene muta-
tion patterns and their prognostic impact in 156.
a cohort of 1185 patients with acute myeloid leukemia. Blood. 2011;118(20): 5593-5603.
21. Ribeiro AF, Pratcorona M, Erpelinck- Verschueren C, et al. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood. 2012;119(24):5824-5831.
22. Tie R, Zhang T, Fu H, et al. Association between DNMT3A mutations and progno- sis of adults with de novo acute myeloid leukemia: a systematic review and meta- analysis. PloS One. 2014;9(6):e93353.
23. Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481(7380):157-163.
24. Bond J, Graux C, Lhermitte L, et al. Early response-based therapy stratification improves survival in adult early thymic pre- cursor acute lymphoblastic leukemia: a group for research on adult acute lym- phoblastic leukemia study. J Clin Oncol. 2017;35(23):2683-2691.
25. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209-2221.
26. Lin ME, Hou HA, Tsai CH, et al. Dynamics of DNMT3A mutation and prognostic rele- vance in patients with primary myelodys- plastic syndrome. Clin Epigenetics. 2018;10:42.
27. Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N
34. Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009;27(6):911-918.
35. Bond J, Marchand T, Touzart A, et al. An early thymic precursor phenotype predicts outcome exclusively in HOXA-overexpress- ing adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. Haematologica. 2016;101(6):732-740.
36. Eguchi-Ishimae M, Eguchi M, Kempski H, Greaves M. NOTCH1 mutation can be an early, prenatal genetic event in T-ALL. Blood. 2008;111(1):376-378.
37. Trinquand A, Tanguy-Schmidt A, Ben Abdelali R, et al. Toward a NOTCH1/FBXW7/RAS/PTEN-based onco- genetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin Oncol. 2013;31 (34):4333-4342.
38. Huguet Fo, Leguay T, Thomas X, et al. The upper age limit for a pediatric-inspired ther- apy in younger adults with Ph-negative acute lymphoblastic leukemia (ALL)? Analysis of the GRAALL-2005 study. 2016:762-762.
39. Metzeler KH, Walker A, Geyer S, et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia. 2012;26(5): 1106-1107.
haematologica | 2019; 104(8)
1625